```
=> b reg
FILE 'REGISTRY' ENTERED AT 17:10:04 ON 12 MAY 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   11 MAY 2010  HIGHEST RN 1222257-16-0
DICTIONARY FILE UPDATES:  11 MAY 2010  HIGHEST RN 1222257-16-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 8, 2010.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> d que sta l9
L5              SCR 1482 OR 1367 OR 1449 OR 1367 OR 1503 OR 1438 OR 1443 O
R 1444
L6              STR
```




```
VAR G1=O/S/N
REP G2=(1-3) C
VAR G3=O/S
VAR G4=9/10/11
REP G5=(0-3) A
VAR G6=17/18/19/23/29/35/36/37/38
VAR G7=N/O
VAR G8=O/N
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  41

STEREO ATTRIBUTES: NONE
L9          818 SEA FILE=REGISTRY SSS FUL L6 AND L5

100.0% PROCESSED 1159668 ITERATIONS                          818 ANSWERS
SEARCH TIME: 00.02.56



=> b zcap
FILE 'ZCAPLUS' ENTERED AT 17:10:11 ON 12 MAY 2010
```

FILE COVERS 1907 - 12 May 2010 VOL 152 ISS 20
FILE LAST UPDATED: 11 May 2010 (20100511/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2010
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2010

ZCAplus now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2010.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> d bib abs hitrn fhitstr l12 tot

L12 ANSWER 1 OF 2 ZCAPLUS COPYRIGHT 2010 ACS on STN
AN 2006:558817 ZCAPLUS
DN 145:63142
TI Preparation of amino acid urea derivatives as factor Xa inhibitors
IN Song, Yonghong; Zhu, Bing-Yan; Wang, Shumei; Bhakta, Chhaya; Scarborough, Robert M.
PA Portola Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 186 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO--2006063113	A2	20060615	2005WO-US044388	20051207
WO--2006063113	A3	20070510		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
US-20060160821	A1	20060720	2005US-000298317	20051207
US-----7678913	B2	20100316		
PRAI 2004US-00634201P	P	20041207		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS CASREACT 145:63142; MARPAT 145:63142
AB The invention relates to urea derivs. A-Q-D-(CR7R8)m(NR6)nCOCR4R5NR3CONR1R2 [m, n are 0 or 1; D is a direct bond, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heteromonocyclyl, heterobicyclyl; Q is a direct bond, alkylene, CO, CS, O, S, imino, SO2, SO, etc. (at least one of D and Q is not a direct bond); A is amino, amidino, guanidino groups, alkyl, pyridyl oxide, etc.; R1 is H, alkyl, arylalkyl, heteroaryl, alkenyl; R2 is (un)substituted arylalkyl, arylcycloalkyl, heteroaryl, cycloalkyl, etc.; R3-R8 are H, (un)substituted alkyl, alkenyl, cycloalkyl, etc.; or R4 may from a ring with R5 or R6] and their pharmaceutically-acceptable salts and prodrugs which are inhibitors of Factor Xa and are used to prevent or treat a number of conditions characterized by undesired thrombosis. Thus, N-[[(4-chlorophenyl)amino]carbonyl]glycine [4-(1-methyl-4,5-dihydro-1H-imidazol-2-yl)phenyl]amide was prepared by reaction of Boc-protected glycine with 4-aminobenzonitrile, iodomethane, N-methylethylenediamine, and 4-chlorophenyl isocyanate. The product showed IC50 ≤ 100 nM for inhibition of factor Xa.
IT **855524-53-7P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of amino acid urea derivs. as factor Xa inhibitors)
IT **855524-53-7P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of amino acid urea derivs. as factor Xa inhibitors)
RN 855524-53-7 ZCAPLUS
CN Urea, N-(4-chlorophenyl)-N'-[(1R)-2-(1'-methyl[4,4'-bipiperidin]-1-yl)-2-oxo-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 1 OF 2 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)



OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

L12 ANSWER 2 OF 2 ZCAPLUS COPYRIGHT 2010 ACS on STN
AN 2005:540568 ZCAPLUS
DN 143:78086
TI Preparation of urea/carbamate derivatives as inhibitors of coagulation factor Xa for treatment of thromoboembolic disorders
IN Cezanne, Bertram; Dorsch, Dieter; Mederski, Werner; Tsaklakidis, Christos; Gleitz, Johannes
PA Merck Patent G.m.b.H., Germany
SO PCT Int. Appl., 80 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO--2005056528	A1	20050623	2004WO-EP0013202	20041119
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE----10358539	A1	20050707	2003DE-100058539	20031215
AU--2004296956	A1	20050623	2004AU-000296956	20041119
CA-----2549548	A1	20050623	2004CA-002549548	20041119
EP-----1694643	A1	20060830	2004EP-000820053	20041119
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
CN-----1890216	A	20070103	2004CN-080036500	20041119
BR--2004017153	A	20070306	2004BR-000017153	20041119
JP--2007513987	T	20070531	2006JP-000544246	20041119
IN----200601578	A	20070504	2006IN-000001578	20060608
MX----2006006593	A	20060731	2006MX-000006593	20060609
KR----2006123305	A	20061201	2006KR-000711538	20060612
US--20070123509	A1	20070531	2006US-000582850	20060614
ZA--200605839	A	20071031	2006ZA-000005839	20060714
PRAI 2003DE-100058539	A	20031215		
2004WO-EP0013202	W	20041119		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS CASREACT 143:78086; MARPAT 143:78086
GI



AB Title compds. I [D = halo, alkoxy, etc.; X = amino, O; Y = O, S, amino, etc.; R1 = H, aryl, heteroaryl, etc.; E = CH, N; Z, Z' = acyl, etc.; Q = O, amino, acyl, etc.; R4-4' = A, OH, alkoxy; T = (hetero)cyclyl, etc.] are prepared For instance, (R)-N-(4-chlorophenyl)-N'-[2-[4-(4-fluorophenyl)piperazin-1-yl]-2-oxo-1-phenylethyl]urea (II) is prepared in 3 steps from 1-methyl-4,4'-bipiperidinyl, (R)-N-(tert-butoxycarbonyl)phenylglycine and 4-chlorophenylisocyanate. II has IC50 = 6 x 10-9 M for Factor Xa. I are inhibitors of coagulation factor Xa and can be used for the prophylaxis and/or the treatment of thromboembolic diseases and for treating tumors.
IT **855524-53-7P**, (R)-N-(4-Chlorophenyl)-N'-[2-(1'-methyl-4,4'-bipiperidinyl-1-yl)-2-oxo-1-phenylethyl]urea **855524-58-2P**, (R)-N-(4-Chlorophenyl)-N'-[2-[4-(4-fluorophenoxy)piperidin-1-yl]-2-oxo-1-phenylethyl]urea **855524-64-0P** **855524-72-0P** **855524-74-2P**, (R)-N-(4-Chlorophenyl)-N'-[2-[4-hydroxy-4-(4-methoxyphenyl)piperidin-1-yl]-2-oxo-1-phenylethyl]urea **855524-76-4P** **855524-77-5P**, (R)-N-(4-Chlorophenyl)-N'-[2-oxo-1-phenyl-2-[4-(1-

L12 ANSWER 2 OF 2 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)
phenylmethanoyl)piperidin-1-yl]ethyl]urea **855524-82-2P** **855524-88-8P** **855524-89-9P**, (R)-N-[2-([4,4']Bipiperidinyl-1-yl)-2-oxo-1-phenylethyl)-N'-(4-chlorophenyl)urea hydrochloride **855524-90-2P**, (R)-N-[2-([4,4'|Bipiperidinyl-1-yl)-1-(4-hydroxyphenyl)-2-oxoethyl)-N'-(4-chlorophenyl)urea hydrochloride **855524-91-3P**, (R)-N-(2-([4,4'|Bipiperidinyl-1-yl)-2-oxo-1-(thiophen-2-yl)ethyl)-N'-(4-chlorophenyl)urea hydrochloride **855524-93-5P**, (R)-N-(4-Chlorophenyl)-N'-[1-(4-hydroxyphenyl)-2-(1'-methyl-4,4'-bipiperidinyl-1-yl)-2-oxoethyl]urea trifluoroacetate **855524-95-7P**, (R)-N-(4-Chlorophenyl)-N'-[2-(1'-methyl-4,4'-bipiperidinyl-1-yl)-2-oxo-1-(thiophen-2-yl)ethyl]urea trifluoroacetate **855524-97-9P**, (R)-N-(4-Chlorophenyl)-N'-[1-(4-hydroxyphenyl)-2-(4-(morpholin-4-yl)piperidin-1-yl)-2-oxoethyl]urea trifluoroacetate **855524-98-0P**, N-[2-([1,4'|Bipiperidinyl-1'-yl)-1-(4-hydroxyphenyl)-2-oxoethyl]-N'-(4-chlorophenyl)urea **855525-00-7P**, (R)-N-(2-([1,4'|Bipiperidinyl-1'-yl)-2-oxo-1-(thiophen-2-yl)ethyl)-N'-(4-chlorophenyl)urea trifluoroacetate **855525-02-9P**, (R)-N-[2-([1,4'|Bipiperidinyl-1'-yl)-2-oxo-1-phenylethyl)-N'-(4-chlorophenyl)urea trifluoroacetate **855525-08-5P** **855525-10-9P** **855525-12-1P**, (R)-N-(4-Chlorophenyl)-N'-[2-(4-(morpholin-4-yl)piperidin-1-yl)-2-oxo-1-(thiophen-2-yl)ethyl]urea trifluoroacetate **855525-14-3P**, (R)-N-[2-([1,4'|Bipiperidinyl-1'-yl)-2-oxo-1-(thiophen-2-yl)ethyl)-N'-(4-chlorophenyl)urea trifluoroacetate **855525-18-7P** **855525-19-8P**, (R)-N-(4-Chlorophenyl)-N'-[2-(1'-methyl-[4,4'|bipiperidinyl-1-yl)-2-oxo-1-(2-chlorophenyl)ethyl]urea **855525-20-1P**, (R)-N-(4-Chlorophenyl)-N'-[2-([4,4'|bipiperidinyl-1-yl)-2-oxo-1-(2-chlorophenyl)ethyl]urea **855525-21-2P** **855525-22-3P** **855525-23-4P**, 4-Chlorophenylcarbamic acid (R)-2-(1'-methyl-4,4'-bipiperidinyl-1-yl)-2-oxo-1-phenylethyl ester **855525-24-5P**, 4-Chlorophenylcarbamic acid (R)-2-(1'-methyl-4,4'-bipiperidinyl-1-yl)-2-oxo-1-phenylethyl ester trifluoroacetate **855525-27-8P**, 4-Chlorophenylcarbamic acid (R)-2-([4,4'|bipiperidinyl-1-yl)-1-(2-chlorophenyl)-2-oxoethyl ester hydrochloride **855525-28-9P**, 4-Chlorophenylcarbamic acid (R)-2-([4,4'|bipiperidinyl-1-yl)-2-oxo-1-phenylethyl ester hydrochloride **855525-30-3P**, 4-Chlorophenylcarbamic acid (R)-1-(2-chlorophenyl)-2-(1'-methyl-4,4'-bipiperidinyl-1-yl)-2-oxoethyl ester trifluoroacetate **855525-32-5P**, 4-Chlorophenylcarbamic acid (R)-1-(2-chlorophenyl)-2-(4-(morpholin-4-yl)piperidin-1-yl)-2-oxoethyl ester trifluoroacetate **855525-34-7P**, 4-Chlorophenylcarbamic acid (R)-2-([1,4'|bipiperidinyl-1'-yl)-1-(2-chlorophenyl)-2-oxoethyl ester trifluoroacetate **855525-36-9P**, 4-Chlorophenylcarbamic acid (R)-2-(4-(morpholin-4-yl)piperidin-1-yl)-2-oxo-1-phenylethyl ester trifluoroacetate **855525-38-1P**, 4-Chlorophenylcarbamic acid (R)-2-([1,4'|bipiperidinyl-1'-yl)-2-oxo-1-phenylethyl ester trifluoroacetate **855525-44-9P** **855525-46-1P** **855525-47-2P**, 4-Chlorophenylcarbamic acid (R)-1-(2,3-difluorophenyl)-2-(1'-methyl-4,4'-bipiperidinyl-1-yl)-2-oxoethyl ester **855525-48-3P**, 4-Chlorophenylcarbamic acid (R)-1-(2-fluorophenyl)-2-(1'-methyl-4,4'-bipiperidinyl-1-yl)-2-oxoethyl ester **855525-49-4P**, 4-Chlorophenylcarbamic acid (R)-1-(2-methoxyphenyl)-2-(1'-methyl-4,4'-bipiperidinyl-1-yl)-2-oxoethyl ester
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of urea/carbamate derivs. as inhibitors of coagulation factor Xa for treatment of thromoboembolic disorders)
IT **855524-53-7P**, (R)-N-(4-Chlorophenyl)-N'-[2-(1'-methyl-4,4'-bipiperidinyl-1-yl)-2-oxo-1-phenylethyl]urea
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of urea/carbamate derivs. as inhibitors of coagulation factor Xa for treatment of thromoboembolic disorders)
RN 855524-53-7 ZCAPLUS
CN Urea, N-(4-chlorophenyl)-N'-[(1R)-2-(1'-methyl[4,4'-bipiperidin]-1-yl)-2-oxo-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 2 OF 2 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d bib abs hitstr l26 tot

L26 ANSWER 1 OF 5 ZCAPLUS COPYRIGHT 2010 ACS on STN
AN 2003:454318 ZCAPLUS
DN 139:36450
TI Preparation of 4-[(piperidylalkyl)ureido]quinolines, 4-[(pyrrolidylalkyl)ureido]quinolines, and analogs as urotensin II receptor antagonists
IN Aissaoui, Hamed; Binkert, Christoph; Clozel, Martine; Mathys, Boris; Mueller, Claus; Nayler, Oliver; Scherz, Michael; Velker, Joerg; Weller, Thomas
PA Actelion Pharmaceuticals Ltd., Switz.
SO PCT Int. Appl., 139 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO--2003048154	A1	20030612	2002WO-EP0013577	20021202 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA-----2473892	A1	20030612	2002CA-002473892	20021202 <--
AU--2002358071	A1	20030617	2002AU-000358071	20021202 <--
AU--2002358071	B2	20080612		
EP-----1499607	A1	20050126	2002EP-000791749	20021202 <--
EP-----1499607	B1	20051207		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
HU--2004002184	A2	20050228	2004HU-000002184	20021202 <--
CN-----1617869	A	20050518	2002CN-000827776	20021202 <--
CN---100424082	C	20081008		
AT------312090	T	20051215	2002AT-000791749	20021202 <--
NZ------534046	A	20060224	2002NZ-000534046	20021202 <--
ES-----2254772	T3	20060616	2002ES-000791749	20021202 <--
NO---2004002844	A	20040823	2004NO-000002844	20040705 <--
MX---2004006599	A	20041207	2004MX-000006599	20040705 <--
ZA---2004005348	A	20051012	2004ZA-000005348	20040705 <--
US--20050043535	A1	20050224	2004US-000501054	20040915 <--
US-----7375227	B2	20080520		
PRAI 2001WO-EP0014195	A	20011204 <--		
2002WO-EP0013577	W	20021202 <--		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS MARPAT 139:36450
GI



I



II

L26 ANSWER 1 OF 5 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

OSC.G 9 THERE ARE 9 CAPLUS RECORDS THAT CITE THIS RECORD (9 CITINGS)
RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 1 OF 5 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)

AB Title (pyridin-4-yl)urea derivs. and related compds. I [wherein Py = (un)substituted 2-NR2R3-pyridin-4-yl, quinolin-4-yl, (5,6,7,8-tetrahydro)[1,8]naphthyridin-4-yl, or 2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl; X = aryl(oxy), arylalkyl, (aryl)alkyl-SO2NR2, aryl-SO2NR2, (aryl)alkyl-CONR2, aryl-CONR2, (aryl)alkyl-NR3CONR2, aryl-NR3CONR2, aroyl, arylalkanoyl, (aryl)alkyl-NR2CO, aryl-NR2CO, etc.; Y = CR4R5(CH2)m or (CH2)mCR4R5; Z = H; or when X = aryl(alkyl), Z = H, OH, CO2H, aryl-CONR2, alkyl-NR2CO, or (aryl)alkyl-NR2CO; m = 1-2; n = 0-1; R1 = H or alkyl; R2 and R3 = independently H or (aryl)alkyl; or NR2R3 = piperidyl, pyrrolidinyl, or morpholinyl; R4 = H, (aryl)alkyl, or aryl; R5 = H or Me; or CR4R5 = carbocyclyl; and enantiomers, diastereomers, racemates, pharmaceutically acceptable salts, solvates, or morphol. forms thereof] were prepared as urotensin II receptor antagonists. For example, reaction of 4-amino-2-methylquinoline with 2-chloroethylisocyanate gave the urea. Substitution with piperidin-4-ylcarbamic acid tert-Bu ester, deprotection of the amine, and coupling with 4-trifluoromethylbenzenesulfonyl chloride provided II. Compds. of the invention inhibited binding of human [125I]-urotensin II to human-derived rhabdomyosarcoma cells in vitro with IC50 values ranging from 0.1 nM to 1000 nM. Thus, I are useful as active ingredients in pharmaceutical compns. for the treatment of vasoconstriction, proliferation, and a wide variety of other disease states associated with urotensin II regulation (no data).
IT **1064717-66-3** **1064717-69-6**
RL: PRPH (Prophetic)
(Preparation of 4-[(piperidylalkyl)ureido]quinolines, 4-[(pyrrolidylalkyl)ureido]quinolines, and analogs as urotensin II receptor antagonists)
RN 1064717-66-3 ZCAPLUS
CN Urea, N-[(1S)-2-methyl-1-[[4-(phenylmethyl)-1-piperidinyl]carbonyl]propyl]-N'-(2-methyl-4-quinolinyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1064717-69-6 ZCAPLUS
CN Urea, N-[2-[4-[(3-methylphenyl)methylene]-1-piperidinyl]-2-oxoethyl]-N'-(2-methyl-4-quinolinyl)- (CA INDEX NAME)

L26 ANSWER 2 OF 5 ZCAPLUS COPYRIGHT 2010 ACS on STN
AN 1998:146699 ZCAPLUS
DN 128:205145
ORE 128:40582n,40583a
TI Piperidine, pyrrolidine and hexahydro-1H-azepine peptide analogs promote release of growth hormone
IN Chen, Meng H.; Nargund, Ravi; Patchett, Arthur A.; Yang, Lihu
PA Merck and Co., Inc., USA
SO U.S., 95 pp., Cont.-in-part of U.S. 5,492,920.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 6

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US-----5721251	A	19980224	1996US-000600912	19960213 <--
US-----5492920	A	19960220	1994US-000323998	19941017 <--
PRAI 1993US-000165149	B2	19931210	<--	
1994US-000323998	A2	19941017	<--	

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS MARPAT 128:205145
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The present invention = directed to certain novel compds. identified as substituted piperidines, pyrrolidines and hexahydro-1H-azepines of the general structural formula I [R1 = e.g., C1-10 alkyl, aryl, aryl(C1-6 alkyl); R3 = e.g., (CH2)q-Ph, (CH2)q-naphthyl, C3-7 cycloalkyl; X = e.g., H, cyano; Y = e.g., H, C1-10 alkyl; R4 and R5 = independently, e.g., H, C1-6 alkyl; A = (CH2)xCR7R7a(CH2)y, Z(CH2)xCR7R7a(CH2)y; x, y = 0-3; Z = NR6a, O; R6a = H, C1-6 alkyl; R7, R7a = independently, e.g., H, C1-6 alkyl, CF3; n = 1-3; q = 0-3]. These compds. promote the release of growth hormone in humans and animals (no data). This property can be utilized to promote the growth of food animals to render the production of edible meat products more efficient, and in humans, to treat physiol. or medical conditions characterized by a deficiency in growth hormone secretion, such as short stature in growth hormone deficient children, and to treat medical conditions which are improved by the anabolic effects of growth hormone. Growth hormone releasing compns. containing such compds. as the active ingredient thereof are also disclosed. Thus, e.g., amide coupling of phenylpiperidine II.HCl (preparation given) with (2R)-N-Boc-amino-5-phenylpentanoic acid followed by deprotection and coupling with N-Boc-4-methylalanine and deprotection afforded piperidine derivative III.HCl.
IT **203941-35-9P** **203941-36-0P** **203941-37-1P**
203941-57-5P **203941-64-4P** **203941-65-5P**
203941-69-9P **203941-70-2P** **203941-73-5P**
203942-14-7P **203942-17-0P** **203942-22-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); FFD (Food or feed use); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of piperidine, pyrrolidine, and hexahydroazepine peptide analogs as growth hormone release promoters)
RN 203941-35-9 ZCAPLUS
CN Benzenepropanamide, 2-[1-[(2R,3R)-3-(1H-indol-3-yl)-1-oxo-2-[[(3R)-3-piperidinylamino]carbonyl]amino]butyl]-4-piperidinyl]-N,N-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.

L26 ANSWER 2 OF 5 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 203941-36-0 ZCAPLUS
CN Benzenepropanamide, 2-[1-[(2R,3R)-3-(1H-indol-3-yl)-1-oxo-2-[[[(3R)-3-piperidinylamino]carbonyl]amino]butyl]-4-piperidinyl]-N,N-dimethyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 203941-35-9
CMF C34 H46 N6 O3

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 203941-37-1 ZCAPLUS

L26 ANSWER 2 OF 5 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)

RN 203941-64-4 ZCAPLUS
CN Benzamide, 2-[1-[(2R,3R)-3-(1H-indol-3-yl)-1-oxo-2-[[[(3R)-3-piperidinylamino]carbonyl]amino]butyl]-4-piperidinyl]-N,N-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 203941-65-5 ZCAPLUS
CN Benzamide, 2-[1-[(2R,3R)-3-(1H-indol-3-yl)-1-oxo-2-[[[(3R)-3-piperidinylamino]carbonyl]amino]butyl]-4-piperidinyl]-N,N-dimethyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 203941-64-4
CMF C32 H42 N6 O3

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

L26 ANSWER 2 OF 5 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)
CN Benzenepropanoic acid, 2-[1-[(2S,3S)-3-(1H-indol-3-yl)-1-oxo-2-[[[(3R)-3-piperidinylamino]carbonyl]amino]butyl]-4-piperidinyl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 203941-57-5 ZCAPLUS
CN 3-Piperidinecarboxamide, N-ethyl-1-[3-(1H-indol-3-yl)-1-oxo-2-[[(3-piperidinylamino)carbonyl]amino]butyl]-4-phenyl-, [3S-[1[2S*(S*),3S*],3α,4α]]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 203941-56-4
CMF C32 H42 N6 O3

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

L26 ANSWER 2 OF 5 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)

RN 203941-69-9 ZCAPLUS
CN Benzamide, 2-[1-[(2R,3R)-3-(1H-indol-3-yl)-2-[[[methyl(3R)-3-piperidinylamino]carbonyl]amino]-1-oxobutyl]-4-piperidinyl]-N,N-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 203941-70-2 ZCAPLUS
CN Benzamide, 2-[1-[(2R,3R)-3-(1H-indol-3-yl)-2-[[[methyl(3R)-3-piperidinylamino]carbonyl]amino]-1-oxobutyl]-4-piperidinyl]-N,N-dimethyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 203941-69-9
CMF C33 H44 N6 O3

Absolute stereochemistry.



L26 ANSWER 2 OF 5 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)

CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 203941-73-5 ZCAPLUS
CN Benzamide, 2-[1-[(2R,3R)-2-[[[(3S)-1-azabicyclo[2.2.2]oct-3-ylamino]carbonyl]amino]-3-(1H-indol-3-yl)-1-oxobutyl]-4-piperidinyl]-N,N-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 203942-14-7 ZCAPLUS
CN 3-Piperidinecarboxamide, N-ethyl-1-[(2R,3R)-3-(1H-indol-3-yl)-2-[[[methyl(3R)-3-piperidinylamino]carbonyl]amino]-1-oxobutyl]-4-phenyl-, (3S,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 203942-17-0 ZCAPLUS
CN Benzenepropanamide, 2-[1-[(3R)-3-(1H-indol-3-yl)-1-oxo-2-[[[(3R)-3-piperidinylamino]carbonyl]amino]butyl]-4-piperidinyl]-N,N-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.

L26 ANSWER 2 OF 5 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 203942-22-7 ZCAPLUS
CN Benzenepropanamide, 2-[1-[(2R,3R)-3-(1H-indol-3-yl)-2-[[[methyl(3R)-3-piperidinylamino]carbonyl]amino]-1-oxobutyl]-4-piperidinyl]-N,N-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.



OSC.G 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (7 CITINGS)
RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 3 OF 5 ZCAPLUS COPYRIGHT 2010 ACS on STN
AN 1998:146698 ZCAPLUS
DN 128:205144
OREF 128:40579a,40582a
TI Di- and trisubstituted piperidine, pyrrolidine and hexahydro-1H-azepine peptide analogs promote release of growth hormone
IN Morriello, Gregori J.; Yang, Linu; Patchett, Arthur A.
PA Merck and Co., Inc., USA
SO U.S., 81 pp., Cont.-in-part of U.S. 5,492,916.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US-----5721250	A	19980224	1996US-000600646	19960213 <--
	US-----5492916	A	19960220	1994US-000323988	19941017 <--
	US-----5622973	A	19970422	1995US-000464982	19950605 <--
PRAI	1993US-000173449	B2	19931223	<--	
	1994US-000323988	A2	19941017	<--	
	1994US-000328988	A3	19941017	<--	

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS MARPAT 128:205144
GI



I



II



III

AB The present invention is directed to certain novel compds. identified as di- and trisubstituted piperidines, pyrrolidines and hexahydro-1H-azepines of the general structural I [R1 = e.g., C1-10 alkyl, aryl, aryl(C1-6 alkyl); X = e.g., H, CN, (CH2)qNR2COR2, (CH2)qNR2SO2(CH2)paryl, (CH2)qNR2SO2R2; Y = e.g., H, C1-10 alkyl, (CH2)paryl; R2 = e.g., H, C1-6 alkyl, C3-7 cycloalkyl; q = 0-4; p = 0-3; R4, R5 = independently, e.g., H, C1-6 alkyl; A = (CH2)xCR7R7a(CH2)y, Z(CH2)xCR7R7a(CH2)y; x, y = independently 0-3; Z = NR6a, O; R6a = H, C1-6 alkyl; R7, R7a = independently, e.g., H, C1-6 alkyl, CF3; n = 1-3]. These compds. promote the release of growth hormone in humans and animals (no data). This property can be utilized to promote the growth of food animals to render the production of edible meat products more efficient, and in humans, to treat physiol. or medical conditions characterized by a deficiency in growth hormone secretion, such as short stature in growth hormone deficient children, and to treat medical conditions which are improved by the anabolic effects of growth hormone. Growth hormone releasing compns. containing such compds. as the active ingredient thereof are also disclosed. Thus, e.g., amide coupling of benzylpiperidinecarboxylate II.HCl (preparation given) with Boc-D-Trp-OH (Boc = Me3CO2C) acid followed by deprotection and coupling with N-Boc-α-methylalanine and deprotection afforded

L26 ANSWER 3 OF 5 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)
piperidine deriv. III.HCl.
IT **203870-63-7P** **203870-64-8P** **203870-65-9P**
203870-66-0P **203870-67-1P** **203870-68-2P**
203870-69-3P **203870-70-6P** **203870-74-0P**
203870-78-4P **203870-94-4P** **203870-95-5P**
203870-96-6P **203870-97-7P** **203870-99-9P**
203871-00-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of di- and trisubstituted piperidine, pyrrolidine, and hexahydroazepine peptide analogs as growth hormone release promoters)
RN 203870-63-7 ZCAPLUS
CN Propanamide, N-[(3S)-1-[(2R)-3-(1H-indol-3-yl)-1-oxo-2-[[[(3R)-3-piperidinylamino]carbonyl]amino]propyl]-3-(phenylmethyl)-3-piperidinyl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 203870-64-8 ZCAPLUS
CN Propanamide, N-[(3S)-1-[(2R)-3-(1H-indol-3-yl)-1-oxo-2-[[[(3R)-3-piperidinylamino]carbonyl]amino]propyl]-3-(phenylmethyl)-3-piperidinyl]-2-methyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 203870-63-7
CMF C33 H44 N6 O3

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

L26 ANSWER 3 OF 5 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)

RN 203870-65-9 ZCAPLUS
CN Methanesulfonamide, N-[(3S)-1-[(2R)-3-(1H-indol-3-yl)-1-oxo-2-[[[(3R)-3-piperidinylamino]carbonyl]amino]propyl]-3-(phenylmethyl)-3-piperidinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 203870-66-0 ZCAPLUS
CN Methanesulfonamide, N-[(3S)-1-[(2R)-3-(1H-indol-3-yl)-1-oxo-2-[[[(3R)-3-piperidinylamino]carbonyl]amino]propyl]-3-(phenylmethyl)-3-piperidinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 203870-65-9
CMF C30 H40 N6 O4 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

L26 ANSWER 3 OF 5 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)
CN 3-Piperidinecarboxamide, N-ethyl-1-[(2R)-3-(1H-indol-3-yl)-1-oxo-2-[[[(3S)-3-(phenylmethyl)-3-piperidinyl]amino]carbonyl]amino]propyl]-3-(phenylmethyl)-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 203870-70-6 ZCAPLUS
CN 3-Piperidinecarboxamide, N-ethyl-1-[(2R)-3-(1H-indol-3-yl)-1-oxo-2-[[[(3S)-3-(phenylmethyl)-3-piperidinyl]amino]carbonyl]amino]propyl]-3-(phenylmethyl)-, (3S)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 203870-69-3
CMF C39 H48 N6 O3

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 203870-74-0 ZCAPLUS
CN 3-Piperidinecarboxamide, N-ethyl-1-[(2R,3R)-3-(1H-indol-3-yl)-1-oxo-2-[[[(3R)-3-piperidinylamino]carbonyl]amino]butyl]-3-(phenylmetnyl)-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.

L26 ANSWER 3 OF 5 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)
RN 203870-67-1 ZCAPLUS
CN 3-Piperidinamine, N-[(dimethylamino)carbonyl]-1-[3-(1H-indol-3-yl)-1-oxo-2-[[(3-piperidinylamino)carbonyl]amino]propyl]-3-(phenylmethyl)-, [3S-[1[S*(S*)],3R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 203870-68-2 ZCAPLUS
CN 3-Piperidinamine, N-[(dimethylamino)carbonyl]-1-[3-(1H-indol-3-yl)-1-oxo-2-[[(3-piperidinylamino)carbonyl]amino]propyl]-3-(phenylmethyl)-, [3S-[1[S*(S*)],3R*]]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 203870-67-1
CMF C32 H43 N7 O3

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 203870-69-3 ZCAPLUS

L26 ANSWER 3 OF 5 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 203870-78-4 ZCAPLUS
CN 3-Piperidinecarboxamide, N-ethyl-1-[(2R,3S)-3-(1H-indol-3-yl)-1-oxo-2-[[[(3R)-3-piperidinylamino]carbonyl]amino]butyl]-3-(phenylmethyl)-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 203870-94-4 ZCAPLUS
CN 3-Piperidinecarboxylic acid, 1-[(2R)-2-[[[(6-amino-2-pyridinyl)amino]carbonyl]amino]-3-(1H-indol-3-yl)-1-oxopropyl]-3-(phenylmethyl)-, ethyl ester, hydrochloride (1:1), (3S)- (CA INDEX NAME)

Absolute stereochemistry.

L26 ANSWER 3 OF 5 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 203870-95-5 ZCAPLUS
CN 3-Piperidinecarboxylic acid, 1-[(2R)-3-(1H-indol-3-yl)-1-oxo-2-[[[(3S)-3-piperidinylamino]carbonyl]amino]propyl]-3-(phenylmethyl)-, ethyl ester, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 203870-96-6 ZCAPLUS
CN 3-Piperidinecarboxylic acid, 1-[(2R)-3-(1H-indol-3-yl)-1-oxo-2-[[[(3R)-3-piperidinylamino]carbonyl]amino]propyl]-3-(phenylmethyl)-, ethyl ester, (3S)- (CA INDEX NAME)

Absolute stereochemistry.

L26 ANSWER 3 OF 5 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 203871-00-5 ZCAPLUS
CN 3-Piperidinecarboxylic acid, 1-[(2R)-3-(1H-indol-3-yl)-2-[[[(4-methyl-4-piperidinyl)amino]carbonyl]amino]-1-oxopropyl]-3-(phenylmethyl)-, ethyl ester, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



IT **203869-88-9P** **203869-91-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of di- and trisubstituted piperidine, pyrrolidine, and hexahydroazepine peptide analogs as growth hormone release promoters)
RN 203869-88-9 ZCAPLUS
CN 1-Piperidinecarboxylic acid, 3-[[[[(1R)-1-(1H-indol-3-ylmethyl)-2-[(3S)-3-[(2-methyl-1-oxopropyl)amino]-3-(phenylmethyl)-1-piperidinyl]-2-oxoethyl]amino]carbonyl]amino]-, 1,1-dimethylethyl ester, (3R)- (CA INDEX NAME)

Absolute stereochemistry.

L26 ANSWER 3 OF 5 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 203870-97-7 ZCAPLUS
CN 3-Piperidinecarboxylic acid, 1-[(2R)-2-[[(1-azabicyclo[2.2.2]oct-3-ylamino)carbonyl]amino]-3-(1H-indol-3-yl)-1-oxopropyl]-3-(phenylmethyl)-, ethyl ester, hydrochloride (1:1), (3S)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 203870-99-9 ZCAPLUS
CN 3-Piperidinecarboxylic acid, 1-[(2R)-3-(1H-indol-3-yl)-2-[[[(3-methyl-3-piperidinyl)amino]carbonyl]amino]-1-oxopropyl]-3-(phenylmethyl)-, ethyl ester, (3S)- (CA INDEX NAME)

Absolute stereochemistry.

L26 ANSWER 3 OF 5 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 203869-91-4 ZCAPLUS
CN 1-Piperidinecarboxylic acid, 3-[[[[(1R)-2-[(3S)-3-[(ethylamino)carbonyl]-3-(phenylmethyl)-1-piperidinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]amino]carbonyl]amino]-3-(phenylmethyl)-, 1,1-dimethylethyl ester, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



OSC.G 11 THERE ARE 11 CAPLUS RECORDS THAT CITE THIS RECORD (12 CITINGS)
RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 4 OF 5 ZCAPLUS COPYRIGHT 2010 ACS on STN
AN 1996:10652 ZCAPLUS
DN 124:203044
OREF 124:37557a,37560a
TI Amino acid-derived piperidides as novel CCKB ligands with anxiolytic-like properties
AU Holladay, Mark W.; Bennett, Michael J.; Bai, Hao; Ralston, Jeffrey W.; Kerwin, James F., Jr.; Stashko, Michael; Miller, Thomas R.; O'Neill, Alyssa; Nadzan, Alex M.; et al.
CS Neuroscience Research, Abbott Lab., Abbott Park, IL, 60064-3500, USA
SO Bioorganic & Medicinal Chemistry Letters (**1995**), 5(24), 3057-62
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier
DT Journal
LA English
AB The development of a novel series of carbamoylamine acid benzoylpiperidides as CCKB ligands is described. Selected members of the series antagonized CCK8-induced calcium mobilization and showed efficacy in the mouse elevated-plus maze, a measure of potential anxiolytic activity.
IT **162881-40-5P** **162881-41-6P** **162881-42-7P**
162881-49-4P **162881-50-7P** **162881-52-9P**
162881-53-0P **162881-55-2P** **162881-59-6P**
162881-60-9P **162881-61-0P** **162881-69-8P**
173986-89-5P **173986-90-8P** **173986-92-0P**
173986-93-1P **173986-94-2P** **173986-95-3P**
173986-96-4P **173986-97-5P** **173986-98-6P**
173987-01-4P **173987-02-5P** **173987-03-6P**
174172-92-0P **174172-93-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of amino acid-derived piperidides as CCK antagonists)
RN 162881-40-5 ZCAPLUS
CN Piperidine, 4-benzoyl-1-[2-[[[(3-methylphenyl)amino]carbonyl]amino]-1-oxo-3-(phenylmethoxy)propyl]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 162881-41-6 ZCAPLUS
CN 1-Piperidinebutanoic acid, 4-benzoyl-β-[[[(3-methylphenyl)amino]carbonyl]amino]-γ-oxo-, phenylmethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L26 ANSWER 4 OF 5 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 162881-52-9 ZCAPLUS
CN Piperidine, 4-(4-fluorobenzoyl)-1-[2-[[[(3-methylphenyl)amino]carbonyl]amino]-1-oxo-3-(phenylmethoxy)propyl]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 162881-53-0 ZCAPLUS
CN 4-Piperidinecarboxamide, 1-[2-[[[(3-methylphenyl)amino]carbonyl]amino]-1-oxo-3-(phenylmethoxy)propyl]-N-phenyl-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 162881-55-2 ZCAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[[[(3-methylphenyl)amino]carbonyl]amino]-3-oxo-3-[4-[(phenylamino)carbonyl]-1-piperidinyl]propyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L26 ANSWER 4 OF 5 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 162881-42-7 ZCAPLUS
CN Piperidine, 4-benzoyl-1-[2-[[[(3-methylphenyl)amino]carbonyl]amino]-1,5-dioxo-5-(1-pyrrolidinyl)pentyl]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 162881-49-4 ZCAPLUS
CN Piperidine, 4-benzoyl-1-[2-[[[(3-methylphenyl)amino]carbonyl]amino]-1-oxo-3-[(phenylmethyl)thio]propyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 162881-50-7 ZCAPLUS
CN Piperidine, 4-benzoyl-1-[2-[[[(3-methylphenyl)amino]carbonyl]amino]-1-oxo-3-[(phenylmethyl)sulfonyl]propyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L26 ANSWER 4 OF 5 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 162881-59-6 ZCAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-(4-benzoyl-1-piperidinyl)-2-[[[(3-methylphenyl)amino]carbonyl]amino]-3-oxopropyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 162881-60-9 ZCAPLUS
CN 4-Morpholinecarboxylic acid, 3-(4-benzoyl-1-piperidinyl)-2-[[[(3-methylphenyl)amino]carbonyl]amino]-3-oxopropyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 162881-61-0 ZCAPLUS
CN Piperidine, 4-benzoyl-1-[2-[[[(3-methylphenyl)amino]carbonyl]amino]-1-oxo-3-[[(phenylamino)carbonyl]oxy]propyl]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L26 ANSWER 4 OF 5 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 162881-69-8 ZCAPLUS
CN 1-Piperidinepentanoic acid, 4-benzoyl-γ-[[[(3-methylphenyl)amino]carbonyl]amino]-δ-oxo-, phenylmethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 173986-89-5 ZCAPLUS
CN Piperidine, 4-benzoyl-1-[4-methyl-2-[[[(3-methylphenyl)amino]carbonyl]amino]-1-oxopentyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 173986-90-8 ZCAPLUS
CN Piperidine, 4-benzoyl-1-[4-methyl-2-[[[(3-methylphenyl)amino]carbonyl]amino]-1-oxopentyl]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L26 ANSWER 4 OF 5 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 173986-92-0 ZCAPLUS
CN Piperidine, 4-benzoyl-1-[2-[[[(3-methylphenyl)amino]carbonyl]amino]-1-oxohexyl]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 173986-93-1 ZCAPLUS
CN 1-Piperidinepentanoic acid, 4-benzoyl-γ-[[[(3-methylphenyl)amino]carbonyl]amino]-δ-oxo-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 173986-94-2 ZCAPLUS
CN Piperidine, 4-benzoyl-1-[2-[[[(3-methylphenyl)amino]carbonyl]amino]-1-oxo-4-phenylbutyl]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 173986-95-3 ZCAPLUS
CN Piperidine, 4-benzoyl-1-[3-(1H-indol-3-yl)-2-[[[(3-

L26 ANSWER 4 OF 5 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)
methylphenyl)amino]carbonyl]amino]-1-oxopropyl]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 173986-96-4 ZCAPLUS
CN Piperidine, 4-benzoyl-1-[2-[[[(3-methylphenyl)amino]carbonyl]amino]-1-oxo-5-phenylpentyl]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 173986-97-5 ZCAPLUS
CN Piperidine, 4-benzoyl-1-[2-[[[(3-methylphenyl)amino]carbonyl]amino]-1-oxo-3-(phenylmethoxy)butyl]-, [R-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 173986-98-6 ZCAPLUS
CN Carbamic acid, dimethyl-, 3-(4-benzoyl-1-piperidinyl)-2-[[[(3-methylphenyl)amino]carbonyl]amino]-3-oxopropyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L26 ANSWER 4 OF 5 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 173987-01-4 ZCAPLUS
CN 1-Piperidinepentanoic acid, 4-(benzoylamino)-γ-[[[(3-methylphenyl)amino]carbonyl]amino]-δ-oxo-, phenylmethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 173987-02-5 ZCAPLUS
CN Piperidine, 1-[2-[[[(3-methylphenyl)amino]carbonyl]amino]-1-oxo-3-(phenylmethoxy)propyl]-4-(phenylmethyl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 173987-03-6 ZCAPLUS
CN 3-Piperidinecarboxamide, 1-[2-[[[(3-methylphenyl)amino]carbonyl]amino]-1-oxo-3-(phenylmethoxy)propyl]-N-phenyl- (CA INDEX NAME)



RN 174172-92-0 ZCAPLUS
CN Piperidine, 4-benzoyl-1-[2-[[[(3-methylphenyl)amino]carbonyl]amino]-1-oxo-3-[(phenylmethyl)sulfinyl]propyl]-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L26 ANSWER 4 OF 5 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 174172-93-1 ZCAPLUS
CN Piperidine, 4-benzoyl-1-[2-[[[(3-methylphenyl)amino]carbonyl]amino]-1-oxo-3-[(phenylmethyl)sulfinyl]propyl]-, [R-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



OSC.G 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)

L26 ANSWER 5 OF 5 ZCAPLUS COPYRIGHT 2010 ACS on STN
AN 1995:538254 ZCAPLUS
DN 122:291527
OREF 122:53179a,53182a
TI Preparation of amino acid amide cholecystokinin antagonists.
IN Kerwin, James F., Jr.; Holladay, Mark W.; Bennett, Michael J.
PA Abbott Laboratories, USA
SO U.S., 42 pp. Cont.-in-part of U.S. Ser. No. 793,414, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US-----5346907	A	19940913	1993US-000017565	19930216 <--
JP----03503650	T	19910815	1989JP-000505008	19890404 <--
EP------442878	A1	19910828	1989EP-000905266	19890404 <--
R: BE, CH, DE, FR, GB, IT, LI, NL, SE				
PRAI 1988US-000177715	B2	19880405	<--	
1989US-000582896	B2	19890404	<--	
1989US-000376778	B2	19890707	<--	
1990US-000793414	B2	19900626	<--	
1989WO-US001412	W	19890404	<--	

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS MARPAT 122:291527
AB ABCONR1CDR2CONR3R4 [A = (substituted) heteroaryl; B = null, O, S, (substituted) ethylene; R1 = H, alkyl; R2 = H, aralkyl, alkyl, cycloalkyl, alkenyl; R2D = (O -interrupted) alkylene; D = H, alkyl, alkenyl, cycloalkyl, (substituted) aryl, heterocyclyl, heterocyclylalkyl, etc.; R3 = H, alkyl, alkoxyalkyl, alkenyl, cycloalkyl, aralkyl, alkoxycarbonylalkyl; R3D = alkylaminocarbonyl, etc.; R4 = alkyl, alkoxyalkyl, alkenyl, aryl, aralkyl, cycoalkyl, cyanoalkyl, alkoxycarbonylalkyl, etc.; NR3R4 = (substituted) heterocyclyl; with provisos], were prepared Thus, BOC-(R)-Val-OH was treated with BOP-Cl, Et3N, and dipentylamine in CH2Cl2 at 0° to give 79% amide, which was deprotected with HCl in dioxane to give 100% (R)-valine dipentylamide hydrochloride. This was treated with EDCI, hydroxybenzotriazole, and quinoline-3-carboxylic acid in CH2Cl2 to give 54% N-(3'-quinolinylcarbonyl)-(R)-valine dipentylamide. This inhibited [125I]-BH-CCK8 binding to pancreatic and cortical membrane prepns. with IC50 = 40 nM and 17,000 nM, resp., and inhibited CCK8-induced amylase release with IC50 = 290 nM.
IT **162881-40-5P** **162881-41-6P** **162881-42-7P**
162881-43-8P **162881-45-0P** **162881-46-1P**
162881-47-2P **162881-48-3P** **162881-49-4P**
162881-50-7P **162881-51-8P** **162881-52-9P**
162881-53-0P **162881-54-1P** **162881-55-2P**
162881-56-3P **162881-57-4P** **162881-58-5P**
162881-59-6P **162881-60-9P** **162881-61-0P**
162881-62-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of amino acid amide cholecystokinin antagonists)
RN 162881-40-5 ZCAPLUS
CN Piperidine, 4-benzoyl-1-[2-[[[(3-methylphenyl)amino]carbonyl]amino]-1-oxo-3-(phenylmethoxy)propyl]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L26 ANSWER 5 OF 5 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 162881-41-6 ZCAPLUS
CN 1-Piperidinebutanoic acid, 4-benzoyl-β-[[[(3-methylphenyl)amino]carbonyl]amino]-γ-oxo-, phenylmethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 162881-42-7 ZCAPLUS
CN Piperidine, 4-benzoyl-1-[2-[[[(3-methylphenyl)amino]carbonyl]amino]-1,5-dioxo-5-(1-pyrrolidinyl)pentyl]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 162881-43-8 ZCAPLUS
CN Piperidine, 4-benzoyl-1-[2-[[[(3-methoxyphenyl)amino]carbonyl]amino]-1,5-dioxo-5-(1-pyrrolidinyl)pentyl]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L26 ANSWER 5 OF 5 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)

RN 162881-45-0 ZCAPLUS
CN Piperidine, 4-benzoyl-1-[1-oxo-2-[[(phenylamino)carbonyl]amino]-3-(phenylmethoxy)propyl]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 162881-46-1 ZCAPLUS
CN Piperidine, 4-benzoyl-1-[2-[[[(3-methoxyphenyl)amino]carbonyl]amino]-1-oxo-3-(phenylmethoxy)propyl]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 162881-47-2 ZCAPLUS
CN Piperidine, 4-benzoyl-1-[2-[[[(3-chlorophenyl)amino]carbonyl]amino]-1-oxo-3-(phenylmethoxy)propyl]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 162881-48-3 ZCAPLUS
CN Piperidine, 1-[2-[[[(3-acetylphenyl)amino]carbonyl]amino]-1-oxo-3-(phenylmethoxy)propyl]-4-benzoyl-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L26 ANSWER 5 OF 5 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 162881-49-4 ZCAPLUS
CN Piperidine, 4-benzoyl-1-[2-[[[(3-methylphenyl)amino]carbonyl]amino]-1-oxo-3-[(phenylmethyl)thio]propyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 162881-50-7 ZCAPLUS
CN Piperidine, 4-benzoyl-1-[2-[[[(3-methylphenyl)amino]carbonyl]amino]-1-oxo-3-[(phenylmethyl)sulfonyl]propyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 162881-51-8 ZCAPLUS
CN Piperidine, 4-benzoyl-1-[2-[[[(3-methylphenyl)amino]carbonyl]amino]-1-oxo-3-[(phenylmethyl)sulfinyl]propyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L26 ANSWER 5 OF 5 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 162881-52-9 ZCAPLUS
CN Piperidine, 4-(4-fluorobenzoyl)-1-[2-[[[(3-methylphenyl)amino]carbonyl]amino]-1-oxo-3-(phenylmethoxy)propyl]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 162881-53-0 ZCAPLUS
CN 4-Piperidinecarboxamide, 1-[2-[[[(3-methylphenyl)amino]carbonyl]amino]-1-oxo-3-(phenylmethoxy)propyl]-N-phenyl-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 162881-54-1 ZCAPLUS
CN 4-Piperidinecarboxamide, 1-[2-[[[(3-methylphenyl)amino]carbonyl]amino]-1,5-dioxo-5-(1-pyrrolidinyl)pentyl]-N-phenyl-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L26 ANSWER 5 OF 5 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 162881-55-2 ZCAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[[[(3-methylphenyl)amino]carbonyl]amino]-3-oxo-3-[4-[(phenylamino)carbonyl]-1-piperidinyl]propyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 162881-56-3 ZCAPLUS
CN Carbamic acid, (phenylmethyl)-, 2-[[[(3-methylphenyl)amino]carbonyl]amino]-3-oxo-3-[4-[(phenylamino)carbonyl]-1-piperidinyl]propyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 162881-57-4 ZCAPLUS
CN Carbamic acid, dimethyl-, 2-[[[(3-methylphenyl)amino]carbonyl]amino]-3-oxo-3-[4-[(phenylamino)carbonyl]-1-piperidinyl]propyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L26 ANSWER 5 OF 5 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 162881-58-5 ZCAPLUS
CN Carbamic acid, diethyl-, 2-[[[(3-methylphenyl)amino]carbonyl]amino]-3-oxo-3-[4-[(phenylamino)carbonyl]-1-piperidinyl]propyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 162881-59-6 ZCAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-(4-benzoyl-1-piperidinyl)-2-[[[(3-methylphenyl)amino]carbonyl]amino]-3-oxopropyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 162881-60-9 ZCAPLUS
CN 4-Morpholinecarboxylic acid, 3-(4-benzoyl-1-piperidinyl)-2-[[[(3-methylphenyl)amino]carbonyl]amino]-3-oxopropyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L26 ANSWER 5 OF 5 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 162881-61-0 ZCAPLUS
CN Piperidine, 4-benzoyl-1-[2-[[[(3-methylphenyl)amino]carbonyl]amino]-1-oxo-3-[[(phenylamino)carbonyl]oxy]propyl]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 162881-62-1 ZCAPLUS
CN 4-Piperidinecarboxamide, N-(3-bromophenyl)-1-[2-[[[(3-methylphenyl)amino]carbonyl]amino]-1-oxo-3-(phenylmethoxy)propyl]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **162881-69-8P** **162881-70-1P** **162881-78-9P**
162881-80-3P **162881-82-5P** **162881-84-7P**
162881-92-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of amino acid amide cholecystokinin antagonists)
RN 162881-69-8 ZCAPLUS
CN 1-Piperidinepentanoic acid, 4-benzoyl-γ-[[[(3-methylphenyl)amino]carbonyl]amino]-δ-oxo-, phenylmethyl ester, (R)-

L26 ANSWER 5 OF 5 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 162881-82-5 ZCAPLUS
CN Piperidine, 4-benzoyl-1-[3-hydroxy-2-[[[(3-methylphenyl)amino]carbonyl]amino]-1-oxopropyl]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 162881-84-7 ZCAPLUS
CN Carbamic acid, [2-(4-benzoyl-1-piperidinyl)-2-oxo-1-[[[(phenylamino)carbonyl]oxy]methyl]ethyl]-, 1,1-dimethylethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 162881-92-7 ZCAPLUS
CN 1-Piperidinepentanoic acid, γ-[[[(3-methylphenyl)amino]carbonyl]amino]-δ-oxo-4-[(phenylamino)carbonyl]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L26 ANSWER 5 OF 5 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 162881-70-1 ZCAPLUS
CN 1-Piperidinepentanoic acid, 4-benzoyl-γ-[[[(3-methoxyphenyl)amino]carbonyl]amino]-δ-oxo-, phenylmethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 162881-78-9 ZCAPLUS
CN 1-Piperidinepentanoic acid, γ-[[[(3-methylphenyl)amino]carbonyl]amino]-δ-oxo-4-[(phenylamino)carbonyl]-, phenylmethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 162881-80-3 ZCAPLUS
CN 4-Piperidinecarboxamide, 1-[3-hydroxy-2-[[[(3-methylphenyl)amino]carbonyl]amino]-1-oxopropyl]-N-phenyl-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L26 ANSWER 5 OF 5 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)



OSC.G 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)
RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> d his

     (FILE 'HOME' ENTERED AT 15:34:49 ON 12 MAY 2010)

     FILE 'ZCAPLUS' ENTERED AT 15:36:31 ON 12 MAY 2010
L1             1 US20070123509 /PN

     FILE 'REGISTRY' ENTERED AT 15:36:44 ON 12 MAY 2010

     FILE 'ZCAPLUS' ENTERED AT 15:36:44 ON 12 MAY 2010
L2             TRA L1 1- RN :       72 TERMS

     FILE 'REGISTRY' ENTERED AT 15:36:44 ON 12 MAY 2010
L3            72 SEA L2
L4            55 L3 AND NC5/ES AND NRS>=3

     FILE 'REGISTRY' ENTERED AT 16:17:10 ON 12 MAY 2010
L5               SCR 1482 OR 1367 OR 1449 OR 1367 OR 1503 OR 1438 OR 1443 OR 144
L6               STR L***
L7             0 L6
L8             1 L6 AND L5
L9           818 L6 AND L5 FULL
L10           41 L9 AND L3
L11          777 L9 NOT L10

     FILE 'ZCAPLUS' ENTERED AT 16:35:30 ON 12 MAY 2010
L12            2 L10
L13           32 L11
L14            1 L13 AND L12
L15           31 L13 NOT L14
L16           21 L15 AND (PRD<20041119 OR AD<=20041119 OR PD<=20041119)
L17           12 L16 AND PD<=20031119
L18            9 L16 NOT L17

     FILE 'REGISTRY' ENTERED AT 16:43:31 ON 12 MAY 2010
L19           73 E1-73
L20          143 E74-216
L21           12 L20 AND (C30H33N3O4 OR C31H35N3O3 OR C28H34N4O2 OR C31H32N4O3 O
L22            7 L20 AND (C30H33N3O3S OR C34H44N6O3 OR C25H29N3O5 OR C30H32FN3O4
L23            7 L20 AND (C30H33N3O4S OR C30H33N3O5S OR C29H30CLN3O4 OR C30H33N3
L24           26 L21-23

     FILE 'ZCAPLUS' ENTERED AT 17:09:13 ON 12 MAY 2010
L25            5 L24
L26            5 L25 AND L17

=>
```